Infliximab is More Effective Than Adalimumab in Ulcerative Colitis
The first statement is correct: Infliximab is more effective than adalimumab in ulcerative colitis, particularly for biologic-naïve patients requiring induction of remission. The 2020 AGA guidelines explicitly recommend infliximab over adalimumab for this indication, and this recommendation is supported by both network meta-analyses and head-to-head trial data.
Guideline-Based Evidence
The 2020 AGA Clinical Practice Guidelines provide the clearest directive: "In adult outpatients with moderate-severe ulcerative colitis who are naïve to biologic agents, the AGA suggests using infliximab or vedolizumab rather than adalimumab, for induction of remission" 1. This is a conditional recommendation with moderate quality evidence.
The British Society of Gastroenterology (2019) corroborates this position, noting that network meta-analyses comparing anti-TNF agents present conflicting data, but the VARSITY head-to-head trial demonstrated vedolizumab's superiority over adalimumab 2. While this doesn't directly compare infliximab to adalimumab, it establishes that not all biologics perform equally.
Comparative Efficacy Data
Induction of Remission
When comparing relative risk ratios from placebo-controlled trials:
- Infliximab: RR 2.85 (95% CI, 2.11–3.86)
- Adalimumab: RR 1.62 (95% CI, 1.15–2.29)
This represents a 76% greater effect for infliximab compared to adalimumab in achieving remission 1.
Maintenance of Remission
For maintenance therapy, the difference narrows but persists:
- Infliximab: RR 2.25 (95% CI, 1.67–3.05)
- Adalimumab: RR 2.28 (95% CI, 1.52–3.42)
These are essentially equivalent for maintenance 1.
Real-World Evidence Considerations
The 2024 AGA evidence synthesis confirms that infliximab demonstrates superior efficacy to adalimumab in biologic-naïve patients, noting this difference is observed across multiple observational studies 3. The mechanism for this difference remains unclear but does not appear related to weight-based dosing of infliximab versus fixed dosing of adalimumab.
Important Nuances from Observational Studies
Several real-world studies show more mixed results:
A 2026 Scandinavian study found no difference in 12-month steroid-free remission (43% infliximab vs 35% adalimumab, p=0.22), but infliximab was superior at 3 months (68% vs 57%, p<0.05) and significantly better in severe disease (70% vs 46%, p<0.05) 4
Multiple Asian population studies found comparable effectiveness between the two agents for colectomy rates, hospitalizations, and corticosteroid requirements 5, 6, 7
Loss of response rates appear similar: annual rates of 10.1% for infliximab versus 13.4% for adalimumab 8
Clinical Decision Algorithm
For biologic-naïve patients with moderate-to-severe UC:
First-line choice: Infliximab (or vedolizumab)
- Particularly for severe disease (Mayo score ≥10)
- When rapid induction is critical
- When maximizing initial response is paramount
Consider adalimumab as alternative when:
- Patient strongly prefers subcutaneous self-administration
- Less severe disease (Mayo score 6-9)
- Patient places higher value on convenience over marginal efficacy difference
- Infusion access is problematic
Both agents are equivalent for:
- Long-term maintenance once remission achieved
- Patients already in remission transitioning therapy
Important Caveats
The efficacy difference is most pronounced during induction, not maintenance. Once patients achieve remission, both agents perform similarly. The AGA acknowledges that patients who value convenience of subcutaneous administration may reasonably choose adalimumab, particularly those with less severe disease 1.
Combination therapy with immunomodulators (azathioprine/6-MP) improves outcomes for both agents and reduces secondary loss of response, with this effect being more pronounced for infliximab 9.
Dose escalation is more frequently required with adalimumab (21.3% annually) compared to infliximab (13.8% annually), though clinical benefit is regained in 72% with infliximab versus 52% with adalimumab after escalation 8.
The statement claiming equal efficacy is not supported by current guidelines or the highest quality comparative evidence, though real-world data suggests the difference may be less pronounced in routine practice than in controlled trials.